This is a 52-week trial comparing adalimumab versus secukinumab for the treatment of active psoriatic arthritis. Both treatments are FDA approved for psoriatic arthritis; however this study seeks to determine which drug is superior.
Subjects must be at least 18 years old and must have a diagnosis of psoriatic arthritis and at least one psoriatic plaque on their skin. Subjects must not have ever taken any biologic drugs for https://premierurgentcare.com/prednisone-online/ psoriatic arthritis such as Humira.
Subjects may receive up to $1490 for participation in this study. All medication and study visits are performed at no cost to the participant.